Oxygen Double Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/177)
-
Patent number: 8753667Abstract: Multi-layered vaginal rings 2 comprising silicone elastomers and pharmaceutically active ingredients are disclosed. The rings comprise a number of layers, at least one of which contains a pharmaceutically active ingredient, and each of which is a silicone elastomer. The multiple layers preferably are produced from these layers of different compositions, including an inner layer 4, a middle layer 5, and an outer layer 6. After extrusion and simultaneous curing, however, the ring 2 includes a contiguous body which comprises a continuous silicone body providing unimpeded diffusion of the pharmaceutically active ingredient from the inner layer (s) 4 to the outer layer (s) 6. Methods of producing these vaginal rings and of using them are also disclosed.Type: GrantFiled: April 7, 2010Date of Patent: June 17, 2014Assignee: The Population Council, Inc.Inventors: Bruce Variano, Jeffrey Speck, Maria Teresa Sallent, Simone Evans
-
Patent number: 8741881Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: June 3, 2014Assignees: Unimed Pharmaceuticals, LLC, Besins Healthcare Luxembourg, SARLInventors: Ramana Malladi, Jodi Stahlman
-
Publication number: 20140147474Abstract: Described are a sterile, ready-to-use, pharmaceutical oil-in water emulsion compositions for parenteral administration comprising: 0.015 to 1.2% wt/vol of progestogen; 0.5-30% wt/vol oil, wherein the oil comprises at least 85% wt/wt triglyceride; 0.0425-12.5% wt/vol phospholipid; 61.4-99.4% wt/vol aqueous medium; wherein the phospholipid is present in an amount of 6.8%-43% of the oil (wt/wt), and wherein the progestogen is present in an amount greater than or equal to 2.1 wt % of the oil. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.Type: ApplicationFiled: June 12, 2013Publication date: May 29, 2014Applicant: BESINS Healthcare Luxembourg SARLInventors: Georg Achleitner, Eva-Maria Hoiser, Laura Pickersgill
-
Publication number: 20140141102Abstract: As disclosed herein, novel compositions including steroid hormones, such as trimegestone (TMG) and progesterone (P4), provide treatments for term and preterm labor with significant effects on the delay of delivery. Delay and block of delivery occurs when both P4 and TMG are administered late in gestation in pregnant rat and guinea pig animal models. TMG exhibits remarkable drug efficacy, achieving the same inhibition as P4, but at much lower doses. These hereto unknown effects of TMG on the processes of cervical ripening and uterine contraction provide a novel approach for extending pregnancy term, including reducing a likelihood of preterm and/or term labor, along with improved methods of administration. Other diseases and/or conditions may be treated with TMG, such as dysmenorrhea or luteal insufficiency for sustaining pregnancy.Type: ApplicationFiled: October 27, 2011Publication date: May 22, 2014Applicant: DIGNITY HEALTHInventors: Robert E. Garfield, Shao-Qing Shi, Leili Shi
-
Publication number: 20140142075Abstract: Provided are methods for increasing fat locally in a body of a subject in need thereof comprising percutaneously administering to the subcutaneous fat of the subject a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, optionally delivered as a composition comprising a pharmaceutically acceptable carrier, as described herein. In certain embodiments, the pharmaceutically acceptable carrier comprises a percutaneous carrier, as described herein. Further provided are compositions comprising a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, for use according to the invention.Type: ApplicationFiled: November 21, 2013Publication date: May 22, 2014Applicant: Topokine Therapeutics, Inc.Inventors: Murat V. Kalayoglu, Michael S. Singer
-
Patent number: 8729057Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: May 20, 2014Assignees: Unimed Pharmaeuticals, LLC, Besins Healthcare Luxembourg SARLInventors: Ramana Malladi, Jodi Stahlman
-
Publication number: 20140128357Abstract: The disclosure relates to methods of using brassinosteroid compounds, including those defined by formula I or a derivative thereof, for inducing an anabolically favorable state for growth, repair, and maintenance of skeletal muscle and skin.Type: ApplicationFiled: December 13, 2011Publication date: May 8, 2014Applicant: Rutgers UniversityInventors: Ilya Raskin, Debora Esposito, Slavko Komarnytsky, Thirumurugan Rathinasabapathy, Leonel Rojo Castillo
-
Publication number: 20140113889Abstract: The present invention comprises a composition and method treating eye diseases using a composition having a therapeutically effective amount of a progestagen and a pharmaceutically acceptable carrier, wherein the composition is applied to the palpebral part of the eye and/or ocular surface.Type: ApplicationFiled: December 23, 2013Publication date: April 24, 2014Applicant: Rhodes Pharmaceuticals, LPInventors: Charles Gerald Connor, Charles L. Haine
-
Patent number: 8691799Abstract: The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK/STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the invention concerns methods of inhibiting the growth of a tumor by administering a cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof, to a patient, wherein the tumor is characterized by the constitutive activation of the JAK/STAT3 intracellular signaling pathway. The present invention further pertains to methods of moderating the JAK and/or STAT3 signaling pathways in vitro or in vivo using cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the present invention concerns a method for screening candidate compounds for JAK and/or STAT3 inhibition and anti-tumor activity.Type: GrantFiled: August 15, 2011Date of Patent: April 8, 2014Assignee: University of South FloridaInventors: Said M. Sebti, Richard Jove
-
Patent number: 8679470Abstract: Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.Type: GrantFiled: November 28, 2008Date of Patent: March 25, 2014Assignee: LuroMed LLCInventors: Adelya K. Leshchiner, Nancy E. Larsen, Edward G. Parent
-
Publication number: 20140066416Abstract: The present invention relates to betulonic and betulinic acid derivatives and, in particular, to C-28 and C-3 derivatives. The present invention relates to betulonic acid esters, and dihydro-betulonic acid esters. Betulinic acid and derivatives thereof may be bound to a poly(alkylene glycol) (PAG) such as poly(ethylene glycol). Binding may be via a linker, such as a diamine, an amino acid, a peptide, an ester or a carbonate. The compounds of the present invention may be used for the treatment of cancer or a viral infection. The present invention also provides pharmaceutical compositions comprising the compounds of the present invention.Type: ApplicationFiled: November 8, 2013Publication date: March 6, 2014Inventor: JEAN-CLAUDE LEUNIS
-
Patent number: 8663681Abstract: The present invention relates to an oral pharmaceutical dosage form comprising micronized progesterone, an edible oil, a disintegrant, and a hydrophilic excipient. Particularly, the invention relates to a pharmaceutical dosage form wherein the dosage form is in a powder form and is contained in a pharmaceutically acceptable capsule. The present invention is also directed toward methods of making the dosage form, methods of using the dosage form, and kits comprising the dosage form.Type: GrantFiled: May 26, 2006Date of Patent: March 4, 2014Assignee: Teva Women's Health, Inc.Inventors: Salah U. Ahmed, Charles E. Diliberti, Chandra Vattikonda, Sudhir R. Gorukanti, Sanjeev K. Gupta
-
Patent number: 8664210Abstract: New aminooxime derivatives at position 3 of 2- and/or 4-substituted androstanes and androstenes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the meanings described in detail in the application.Type: GrantFiled: September 18, 2008Date of Patent: March 4, 2014Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Alberto Cerri, Giuseppe Bianchi, Giorgio Fedrizzi, Patrizia Ferrari, Mauro Gobbini, Marco Torri, Giuseppe Marazzi, Walter Cabri
-
Publication number: 20140045805Abstract: This invention is generally related to the fields of fragrance compositions, personal care products, and home consumer products. This invention also relates to 20-pregnenes, in particular those found naturally occurring in corals and which affect mood in humans, to the incorporation of these 20-pregnene compounds into various compositions, and to methods of affecting the mood of individuals using such compounds.Type: ApplicationFiled: March 26, 2013Publication date: February 13, 2014Applicant: Human Pheromone Sciences, Inc.Inventor: Human Pheromone Sciences, Inc.
-
Patent number: 8642567Abstract: The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in treating central nervous system disorders by over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of enhancing brain's cognitive function and reducing neuronal cell death in mammals and humans.Type: GrantFiled: November 10, 2009Date of Patent: February 4, 2014Assignee: The Hong Kong University of Science and TechnologyInventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu, Wen Cai Ye
-
Publication number: 20140030311Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.Type: ApplicationFiled: October 3, 2013Publication date: January 30, 2014Applicant: TEVA WOMEN'S HEALTH, INC.Inventors: Salah U. AHMED, Jiaxiang TSAO, Anu MAHASHABDE, Diane D. HARRISON
-
Publication number: 20140031326Abstract: The invention relates to methods for the treatment of fibromyalgia and chronic fatigue syndrome by administration of a transdermally applied androgen composition. The treatment is both safe and effective for treating fibromyalgia-related pain and fatigue, as well as chronic fatigue syndrome.Type: ApplicationFiled: November 17, 2011Publication date: January 30, 2014Applicant: WHITE MOUNTAIN PHARMA. INC.Inventors: Hillary D. White, Robert Gyurik
-
Publication number: 20140024627Abstract: The current invention provides a new and original method for treatment of ocular inflammatory diseases. More particularly, the present invention relates a mineralocorticoid receptor agonist for use in the treatment of an ocular inflammatory disease.Type: ApplicationFiled: January 3, 2012Publication date: January 23, 2014Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DESCARTESInventors: Francine Behar-Cohen, Elodie Bousquet
-
Patent number: 8633179Abstract: The present invention relates to methods and compositions for preventing and/or treating various conditions in a patient, including for example, T-cell lymphoblastic leukemia and lymphoma as well as neurodegenerative diseases, such as for example, Alzheimer's disease. In one preferred embodiment of the invention, such methods include providing a patient with an effective amount of a combination of a NOTCH-1 inhibitor and glucocorticoid. The present invention further encompasses methods for increasing the efficacy of, and mitigating resistance to, glucocorticoids in the treatment of T-cell lymphoblastic leukemia and lymphoma, which generally include providing a patient with an effective amount of one or more NOTCH-1 inhibitors.Type: GrantFiled: March 13, 2008Date of Patent: January 21, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventors: Adolfo A. Ferrando, Pedro J. Real
-
Publication number: 20130345187Abstract: A method of genotyping women experiencing infertility for non-physical reasons in order to identify the presence of the rs4238001 and/or rs10846744 mutation of the SCARB1 gene and, upon identifying the presence of one or both genetic mutations, administering a tailored therapeutic regimen to restore fertility by either one or a combination of 1) mediating the flux of cholesterol resulting from the mutation by therapeutic use of the cholesterol medication probucol and/or other cholesterol altering medications, and/or 2) amplifying the presence of hormone progesterone by therapeutic use of progestational and progestin medications.Type: ApplicationFiled: December 6, 2012Publication date: December 26, 2013Inventor: Annabelle Rodriguez Oquendo
-
Patent number: 8614203Abstract: The present invention provides methods for the treatment or the prevention of neuronal damage in the CNS. Specifically, the methods of the invention provide for the administration of a therapeutically effective amount of a progestin or progestin metabolite following a traumatic or ischemic injury to the CNS such that, prior to termination of administration of the progestin or progestin metabolite the administration is tapered to avoid withdrawal. The drug taper employed can involve a linear taper, an exponential taper, progressively dividing administered doses by 50%, or can be determined based on the treating physician's assessment of the patient's response to therapy. The tapered administration methods of the present invention may be used in combination with any therapeutic protocol or regimen for the administration of a therapeutically effective amount of a progestin or progestin metabolite to treat a traumatic or ischemic CNS injury.Type: GrantFiled: July 16, 2012Date of Patent: December 24, 2013Assignee: Emory UniversityInventors: Donald G. Stein, Sarah Cutler
-
Publication number: 20130338123Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.Type: ApplicationFiled: March 15, 2013Publication date: December 19, 2013Inventors: Brian A. Bernick, Janice Louise Cacace, Peter H.R. Persicaner, Neda Irani, Julia M. AMADIO
-
Publication number: 20130338122Abstract: Hormone replacement therapies are provided comprising solubilized progesterone alone and optionally with an estrogen, cyclic/sequential and continuous-combined dosing, and administered via transdermal HRT delivery systems.Type: ApplicationFiled: March 15, 2013Publication date: December 19, 2013Applicant: THERAPEUTICSMD, INC.Inventors: Brian A. Bernick, Julia M. Amadio, Peter H.R. Persicaner, Janice Louise Cacace, Neda Irani
-
Patent number: 8604011Abstract: In one aspect the present invention provides neuroactive steroids for use in the treatment of nervous system disorders, degenerative brain diseases and congenital storage diseases. In a second aspect the invention provides neuroactive steroids in combination with a Liver X Receptor (LXR) ligand to effect treatment of a nervous system condition.Type: GrantFiled: September 27, 2005Date of Patent: December 10, 2013Assignee: The Regents of the University of CaliforniaInventor: Synthia Mellon
-
Publication number: 20130323330Abstract: A method of treating prostate cancer by administering a pharmaceutically-acceptable amount of a crude extract of the indigenous Jamaican plant Ball Moss (Tillandsia Recurvata) comprising one or more cycloartane isolates, and the isolates used in the method for eliciting thereby a kinase inhibitory response of prostate cancer cells by selectively inhibiting MRCK? kinase and angiogenesis of (growth of new blood vessels) to reduce the viability of prostate cancer cells. The method and compounds holds promise as a chemopreventive agent, without causing excessive damage to normal cells.Type: ApplicationFiled: June 5, 2013Publication date: December 5, 2013Inventors: Henry Lowe, Joseph Bryant, DVM
-
Publication number: 20130310350Abstract: Use of compounds disclosed herein, typically progesterone or analog or derivative thereof, in the treatment of central nervous system cancers, specifically neuroblastoma and glioblastoma is provided. The treatment offers a reduced toxicity as compared to the currently available chemotherapeutic agents. The progesterone may be administered alone or in combination with, or in conjunction with other therapeutic agents.Type: ApplicationFiled: March 4, 2013Publication date: November 21, 2013Applicant: EMORY UNIVERSITYInventors: Donald G. Stein, Iqbal Sayeed, Fahim Atif
-
Patent number: 8586568Abstract: The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.Type: GrantFiled: March 25, 2011Date of Patent: November 19, 2013Assignee: Ampio Pharmaceuticals, Inc.Inventor: David Bar-Or
-
Patent number: 8580293Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.Type: GrantFiled: February 3, 2009Date of Patent: November 12, 2013Assignee: Teva Women's Health, Inc.Inventors: Salah U. Ahmed, Jiaxiang Tsao, Anu Mahashabde, Diane D. Harrison
-
Patent number: 8569376Abstract: Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR1, —SR2, or —NR3R4, and R1, R2, R3, R4, R5, R6, R7, R7?, Z, Y, n, y, and x, are as defined herein.Type: GrantFiled: March 1, 2013Date of Patent: October 29, 2013Assignee: Topokine Therapeutics, Inc.Inventors: Murat V. Kalayoglu, Michael S. Singer
-
Patent number: 8546363Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: GrantFiled: July 15, 2010Date of Patent: October 1, 2013Assignee: Otonomy, Inc.Inventors: Qiang Ye, Luis A. Dellamary
-
Patent number: 8541399Abstract: A sterile composition of a pharmaceutical compound is prepared by combining solvent with a non-sterile pharmaceutical compound to form a solution and filtering to yield a sterile pharmaceutical compound, optionally removing all or part of the solvent, and under sterile conditions combining the compound with a pharmaceutically acceptable carrier.Type: GrantFiled: February 19, 2003Date of Patent: September 24, 2013Assignee: Resolution Chemicals LimitedInventors: Parveen Bhatarah, Kenneth Alan Greenwood
-
Publication number: 20130225412Abstract: The various embodiments herein provide a nano silicon carrier as a drug delivery mechanism. The nano silicon carrier comprises a diatom frustules loaded with a drug molecule to be released at the target site. The diatom frustules are of Hannaea arcus and Navicula inflexa species of diatom. The pore size of the diatom frustules is 1 to 100 nm. The diatom frustules are comb-like in structure. The diatom frustules are in the form of powdered diatomaceous earth. The drug delivery mechanism described in the embodiments herein is a controlled release mechanism. The nano silicon carrier described in the embodiments herein is also used for delivery of pesticides and herbicides in plants. The nano silicon carrier described in the embodiments herein is also used in hormone waste water treatment.Type: ApplicationFiled: February 28, 2012Publication date: August 29, 2013Inventors: Soroush Sardari Lodriche, Saeed Soltani, Roghieh Mirzazadeh
-
Patent number: 8518924Abstract: To reduce amounts of fat accumulated in abdominal cavity and to prevent or ameliorate visceral fat type obesity, considered to be a main factor of metabolic syndrome, the present invention provides an agent or a food or drink which contains a compound having a lophenol skeleton, or an organic solvent extract or a hot water extract of a Liliaceae plant, or a fraction thereof containing the compound as an active ingredient.Type: GrantFiled: July 21, 2010Date of Patent: August 27, 2013Assignee: Morinaga Milk Industry Co., Ltd.Inventors: Miyuki Tanaka, Eriko Misawa
-
Patent number: 8518921Abstract: Compositions useful for inducing bone growth or inhibiting bone loss in an animal comprising one or more isoflavones or isoflavone metabolites and methods for inducing bone growth or inhibiting bone loss in an animal utilizing such compositions. The compositions and methods are particularly useful for post-menopause, post-andropause, gonadectomized, spayed, or neutered animals.Type: GrantFiled: July 2, 2012Date of Patent: August 27, 2013Assignee: Nestec SAInventor: Yuanlong Pan
-
Publication number: 20130210785Abstract: This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke.Type: ApplicationFiled: February 14, 2013Publication date: August 15, 2013Applicant: EMORY UNIVERSITYInventor: Emory University
-
Publication number: 20130209538Abstract: The present invention relates to a biodegradable ocular implant for sustained drug delivery, comprising a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed.Type: ApplicationFiled: August 12, 2011Publication date: August 15, 2013Applicants: SINGAPORE HEALTH SERVICES PTE LTD, NANYANG TECHNOLOGICAL UNIVERSITYInventors: Subramanian Venkatraman, Yin Chiang Freddy Boey, Tina Wong, Jodhbh Metha
-
METHOD FOR POST COITAL CONTRACEPTION IN OVERWEIGHT OR OBESE FEMALE SUBJECTS USING ULIPRISTAL ACETATE
Publication number: 20130210788Abstract: The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese.Type: ApplicationFiled: December 1, 2010Publication date: August 15, 2013Applicant: LABORATOIRE HRA-PHARMAInventors: Delphine Levy, Andre Ulmann, Henri Camille Mathe, Erin Gainer -
Patent number: 8507467Abstract: A transdermally absorbable preparation comprises a natural type sex hormone, a polyoxyethylene oleyl ether having a molar number of ethylene oxide units added of 20, at least two kinds of oily ingredients selected from the group consisting of diisopropyl adipate, cetyl alcohol, benzyl alcohol, and propylene glycol dicaprate, a polyhydric alcohol, and ethanol.Type: GrantFiled: September 10, 2008Date of Patent: August 13, 2013Assignee: Shiseido Company, Ltd.Inventors: Rakan Matsui, Osamu Ueda
-
Publication number: 20130203718Abstract: The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.Type: ApplicationFiled: May 9, 2011Publication date: August 8, 2013Inventors: Marie-Edith Rafestin-Oblin, Mouad Alami, Hugues Loosfelt, Abdallah Hamze, Ali Junaid Khan, Abdellatif Tikad, Marc Lombes, Jean-Daniel Brion
-
Patent number: 8501719Abstract: The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of DHEA per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of DHEA per day to the female for at least four months.Type: GrantFiled: October 30, 2009Date of Patent: August 6, 2013Assignee: American Infertility of New YorkInventors: Norbert Gleicher, David H. Barad, Dwyn V. Harben
-
Patent number: 8501718Abstract: The present invention is directed to a method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering dehydroepiandrosterone to the female for at least about one month, and evaluating a second anti-Müllerian hormone level of the female, wherein the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level.Type: GrantFiled: October 7, 2009Date of Patent: August 6, 2013Assignee: American Infertility of New YorkInventors: Norbert Gleicher, David H. Barad, Dwyn V. Harben
-
Publication number: 20130196963Abstract: The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: Temple University - Of The Commonwealth System of Higher EducationInventor: Temple University - Of The Commonwealth System of Higher Education
-
Publication number: 20130196959Abstract: The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: Temple University - Of The Commonwealth System of Higher EducationInventor: Temple University - Of The Commonwealth System of Higher Education
-
Publication number: 20130196962Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.Type: ApplicationFiled: April 5, 2011Publication date: August 1, 2013Applicant: VALIDUS BIOPHARMA, INCInventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
-
Publication number: 20130189333Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.Type: ApplicationFiled: January 18, 2013Publication date: July 25, 2013Applicant: ALTRIA CLIENT SERVICES INC.Inventor: Altria Client Services Inc.
-
Patent number: 8492368Abstract: Compositions and methods for treating traumatic brain injury (TBI) and mild traumatic brain injury (mTBI) using progesterone and ent-progesterone are described.Type: GrantFiled: October 5, 2012Date of Patent: July 23, 2013Assignee: Florida State University Research FoundationInventors: Jacob W. Vanlandingham, John Suber, Michael Lewandowski
-
Publication number: 20130184244Abstract: Processes for preparing lanostane triterpenes from the medicinal mushroom Ganoderma lucidum, and related compounds are described. Compounds, compositions, and methods for treating cancer are also described.Type: ApplicationFiled: September 29, 2011Publication date: July 18, 2013Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: Robert Minto, Erin Kennedy
-
Patent number: 8486925Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: October 5, 2011Date of Patent: July 16, 2013Assignees: Unimed Pharmaceuticals, LLC, Laboratoires Besins International, SASInventors: Ramana Malladi, Jodi Miller
-
Patent number: 8481515Abstract: The object of the invention is the use as a drug of a compound fitting formula I wherein X represents an oxygen atom or a ?N—OH group and R represents a group selected from or one of its esters and/or of its addition salts with pharmaceutically acceptable acids, particularly as a cytoprotective drug, preferentially a cardioprotective and/or neuroprotective drug, the compounds of formula I wherein R is R2, R3, R4, R5 or R6 as novel compounds as well as their preparation method and use.Type: GrantFiled: December 15, 2006Date of Patent: July 9, 2013Assignee: TrophosInventors: Cyrille Drouot, Delphine Maux
-
Patent number: 8476252Abstract: Described are a sterile, ready-to-use, pharmaceutical oil-in water emulsion compositions for parenteral administration comprising: 0.015 to 1.2% wt/vol of progestogen; 0.5-30% wt/vol oil, wherein the oil comprises at least 85% wt/wt triglyceride; 0.0425-12.5% wt/vol phospholipid; 61.4-99.4% wt/vol aqueous medium; wherein the phospholipid is present in an amount of 6.8%-43% of the oil (wt/wt), and wherein the progestogen is present in an amount greater than or equal to 2.1 wt % of the oil. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.Type: GrantFiled: April 25, 2011Date of Patent: July 2, 2013Assignee: Besins Healthcare Luxembourg SARLInventors: Georg Achleitner, Eva-Maria Hoiser, Laura Pickersgill